American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of …

A Cuker, EK Tseng, R Nieuwlaat… - Blood …, 2021 - ashpublications.org
Abstract Background: COVID-19–related critical illness is associated with an increased risk
of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the …

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of …

A Cuker, EK Tseng, R Nieuwlaat… - Blood …, 2022 - ashpublications.org
Abstract Background: COVID-19–related acute illness is associated with an increased risk of
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

A Cuker, EK Tseng, R Nieuwlaat… - Blood …, 2021 - ashpublications.org
Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute illness
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence …

Thromboprophylaxis in patients with COVID-19: systematic review of national and international clinical guidance reports

KG Kyriakoulis, A Kollias, IG Kyriakoulis… - Current Vascular …, 2022 - ingentaconnect.com
Background: Venous Thromboembolism (VTE) is common among patients with severe
Coronavirus Disease 2019 (COVID-19). Anticoagulation in hospitalized COVID-19 patients …

Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis

S Zhang, Y Li, G Liu, B Su - Thrombosis Journal, 2021 - Springer
Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

[HTML][HTML] Good practice statements for antithrombotic therapy in the management of COVID‐19: guidance from the SSC of the ISTH

AC Spyropoulos, JM Connors, JD Douketis… - Journal of Thrombosis …, 2022 - Elsevier
Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …

Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum

GD Barnes, A Burnett, A Allen, J Ansell… - Journal of thrombosis …, 2022 - Springer
Thromboembolism is a common and deadly consequence of COVID-19 infection for
hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and …

Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among …

S Mazloomzadeh, S Khaleghparast, B Ghadrdoost… - Jama, 2021 - jamanetwork.com
Importance Thrombotic events are commonly reported in critically ill patients with COVID-19.
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta …

L Ortega-Paz, M Galli, D Capodanno… - European Heart …, 2022 - academic.oup.com
Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …

Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future …

A Flaczyk, RP Rosovsky, CT Reed… - Critical Care, 2020 - Springer
Critically ill patients with COVID-19 are at increased risk for thrombotic complications which
has led to an intense debate surrounding their anticoagulation management. In the absence …